

UNITYPOINT HEALTH - MERITER LABORATORIES
TEST ANNOUNCEMENT
BioFire Respiratory Panel

10/15/2024

Starting October 28th, 2024, molecular respiratory pathogen panel testing will switch to the BioFire Torch platform. The Respiratory Panel 2.1 is a PCR-based, multiplexed *in vitro* diagnostic test that uses a syndromic approach to detect and identify pathogens most associated with upper respiratory tract infections. This test is intended for patients who are seriously ill or are at risk for complications.

The BioFire Respiratory 2.1 Panel includes 22 pathogen targets:

Adenovirus

Coronavirus 229E

Coronavirus HKU1 Coronavirus NL63

Coronavirus OC43

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Human metapneumovirus

Human rhinovirus/enterovirus

Influenza A virus

Influenza A virus A/H1

Influenza A virus A/H3

Influenza A virus A/H1-2009

Influenza B virus

Parainfluenza virus 1

Parainfluenza virus 2

Parainfluenza virus 3

Parainfluenza virus 4

Respiratory syncytial virus

Bordetella parapertussis

Bordetella pertussis

Chlamydia pneumoniae

Mycoplasma pneumoniae

	Current In-House Test	New In-House Test
Test Name	Respiratory Pathogens PCR Panel	Respiratory FilmArray Panel
Epic EAP	LAB6404	LAB3189
SQ Code	RESPCR	RESP21
Specimen	NP Swab in UTM	NP Swab in UTM

Performing Laboratory: Meriter Laboratories

Methodology: Molecular

Specimen Requirements: Nasopharyngeal Swab (NPS) collected according to standard technique and immediately placed in Universal Viral Transport Media.

Specimen Handling and Transport:

2-8°C for up to 72 hours

Ambient up to 4 hours

Performed: Monday through Sunday

Turn-around Time:

STAT: 4 hours

Routine: 24 hours

CPT: 0202U

If you have any questions, please call the UnityPoint Health - Meriter Laboratories Client Services Department at 608-417-6529 or 1-800-236-0465.